| Title | Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. | | Author(s) | Biederman J, Spencer TJ, Wilens TE, Weisler RH, Read SC, Tulloch SJ, SLI381.304 study group | | Institution | Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. jbiederman@partners.org | | Source | CNS Spectr 2005 Dec; 10(12 Suppl 20):16-25. | | MeSH | Administration, Oral
Adult
Adverse Drug Reaction Reporting Systems
Amphetamines
Attention Deficit Disorder with Hyperactivity
Comparative Study
Delayed-Action Preparations
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Long-Term Care
Male
Quality of Life
Treatment Outcome
| | Abstract | OBJECTIVE: Assess the long-term safety and effectiveness of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD) combined subtype.
METHODS: A 24-month, open-label extension of a 4-week, multicenter, double-blind, placebo-controlled, parallel-group, forced-dose-escalation study of MAS XR in adults (>or=18 years of age) with ADHD. The 223 enrolled subjects started treatment at 20 mg/day for 1 week, with subsequent titration up to 60 mg/day for optimal therapeutic effects. At monthly visits, efficacy was assessed based on the ADHD Rating Scale IV (ADHD-RS-IV). Safety assessments included spontaneously reported adverse events, laboratory assessments, and monitoring of vital signs.
FINDINGS: ADHD symptoms significantly improved for all subjects as measured by change from baseline in mean ADHD-RS-IV total scores (-7.2+/-13.04 unit points; P<.001); this was sustained for up to 24 months. The most common treatment-related adverse events were dry mouth (43% of subjects reporting at least one occurrence), infection (33%), insomnia (32%), anorexia/decreased appetite (32%), headache (30%), and nervousness (26%). Most adverse events were mild to moderate in intensity.
CONCLUSION: Treatment with MAS XR 20-60 mg/day for adult ADHD was generally well tolerated and was associated with sustained symptomatic improvement for up to 24 months. | | Language | eng | | Pub Type(s) | Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 16344837 |
|
